$199.99
Retatrutide 20mg — also written Reta, reta peptide or R3TA — supplied from Australian stock as a reference material for laboratory research.
Retatrutide (LY3437943) is a triple agonist at the GLP-1, GIP and glucagon receptors. It is an investigational compound and is not approved by the Therapeutic Goods Administration or any other regulator.
This lot: assayed by Janoshik on a blind GLP-1 panel at 99.782% purity, 23.13mg measured content. Verification code 9T9X1MICT9RW — check it yourself at janoshik.com/verify, or read the full report on our certificates page.
Dispatched Australia-wide with Express Post, 1–2 business days from payment clearance. For scientific research and laboratory use only. Not for human or veterinary consumption.
Free Delivery on all orders above $550
29 in stock
Australian Peptides supplies Retatrutide 20mg — as a reference for laboratory research. Each vial holds 20mg of lyophilised retatrutide peptide. We seal every vial under vacuum and ship from Australian stock. This product is strictly for laboratory use only, and not for human or animal use, consumption, or therapeutic use.
Retatrutide, known in the literature as LY3437943, is an investigational peptide that acts as a triple agonist at three receptors at once: GLP-1, GIP and glucagon. That distinguishes it from semaglutide, which targets GLP-1 alone, and from tirzepatide, which targets GLP-1 and GIP. The addition of glucagon receptor activity is the reason retatrutide is studied separately rather than as another entry in the same class.
It is an investigational compound. Retatrutide has not been approved by the Therapeutic Goods Administration, the FDA, the EMA or any other regulator, in Australia or elsewhere. It is not a medicine, and nothing on this page describes a use in people.
Retatrutide has been through Phase 2 clinical study, with results published in the New England Journal of Medicine in 2023. That trial examined body-weight change in adults with obesity over 48 weeks, and reported a mean reduction of approximately 24% at the highest dose studied. Separate Phase 2 work has examined type 2 diabetes. Phase 3 programmes are ongoing.
Those are findings from controlled clinical trials conducted under medical supervision, reported here as published literature. They describe what investigators observed in a trial population. They are not a claim about this product, and they are not guidance for use.
Retatrutide is written several ways, and all of them refer to the same compound. Reta and reta peptide are the common short forms, used in research communities and in most of the search traffic that reaches this page. R3TA is the marking on our vial label and the name this product carried on this site until recently. LY3437943 is the development code used in the clinical literature.
If you arrived here searching for reta, reta peptide, R3TA or retatrutide 20mg, this is the page you wanted.
Retatrutide 20mg ships as a white to off-white lyophilised powder in a sealed glass vial. The vial carries a rubber stopper and an aluminium crimp seal. We add no excipients, carriers or preservatives. Because we fill and seal under vacuum, moisture uptake stays low during storage and transit.
The current lot was assayed by Janoshik and reports 99.782% purity, with measured content of 23.13mg against a 20mg label. The report was run as a blind GLP-1 panel — the laboratory screened for semaglutide, tirzepatide and retatrutide without being told which to expect, which is a materially harder test to pass than an assay aimed at a single expected compound.
The report carries verification code 9T9X1MICT9RW, which you can enter at janoshik.com/verify to confirm the result with the laboratory rather than with us. The full report, alongside every other certificate we hold, is published on our certificates of analysis page.
The 10mg vial is also available. Researchers who work through material quickly often prefer the larger size, because fewer vials means fewer stopper piercings and less handling loss. Both sizes come from the same production runs, so a certificate of analysis applies to either size whenever the lot number matches.
Lyophilised retatrutide stays stable at ambient temperature in transit. However, move it to -20°C on arrival and keep it away from direct light. To reconstitute, add bacteriostatic water; the resulting concentration depends on the volume of diluent added and on the protocol the laboratory is following.
Direct the diluent slowly down the inside wall of the vial rather than onto the powder. Then swirl gently. Never shake the vial, because agitation can shear the peptide chain and degrade the sample.
Dispatched from Australian stock with Australia Post Express Post. Processing takes 1–2 business days from payment clearance. Transit is 2–4 business days to metro Melbourne, Sydney, Brisbane and Adelaide, 4–7 to regional areas, and 5–10 to Perth, Darwin, Tasmania and remote areas. Free delivery on orders over $550. Full terms are on our shipping policy page.
Yes. Reta is simply the short form. R3TA is the same compound again — it is what appears on the vial label. There is no difference in material between anything sold under those names here.
From this page. Stock is held in Australia and dispatched domestically with Australia Post Express Post, so there is no international transit and no customs step. Both the 10mg and 20mg vials are available.
Retatrutide 10mg is $119.99 and retatrutide 20mg is $199.99. Delivery is free on orders over $550; below that it is calculated at checkout on weight, order value and destination. Those are the current prices on this page — we do not quote a different figure anywhere else.
The material is identical and comes from the same production runs; only the quantity in the vial differs. Researchers working through material quickly generally prefer the 10mg vial, because fewer vials means fewer stopper piercings and less handling loss. A certificate of analysis applies to either size whenever the lot number matches.
Because you can check it without us. This lot was assayed by Janoshik, and the report carries verification code 9T9X1MICT9RW. Enter that code at janoshik.com/verify and the laboratory confirms the result directly. The report was run as a blind GLP-1 panel — the laboratory screened for semaglutide, tirzepatide and retatrutide without being told which to expect, which is a harder test to pass than an assay aimed at one expected compound. Measured content was 23.13mg against a 20mg label. Every certificate we hold is published on our certificates of analysis page, including the three where the issuing laboratory obscured the code — those are marked as unverifiable rather than left to look otherwise.
Payment is by bank transfer. Processing takes 1–2 business days from payment clearance, and a bank transfer may add a further 1–3 business days at the bank’s end. After dispatch, Express Post transit is 2–4 business days to metro Melbourne, Sydney, Brisbane and Adelaide, 4–7 to regional areas, and 5–10 to Perth, Darwin, Tasmania and remote areas. Full terms are on the shipping policy page.
Lyophilised material is stable at ambient temperature in transit. On arrival, move it to -20°C and keep it away from direct light. To reconstitute, add bacteriostatic water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Never shake it — agitation can shear the peptide chain and degrade the sample.
No. Retatrutide is an investigational compound. It has not been approved by the Therapeutic Goods Administration, the FDA, the EMA or any other regulator, in Australia or elsewhere. It is not a medicine, and it is supplied here for scientific research and laboratory use only.
Retatrutide 20mg is supplied for scientific research and laboratory use only. It is not a therapeutic good, is not approved by the Therapeutic Goods Administration, and is not for human or veterinary consumption. Nothing on this page is a claim that retatrutide treats, prevents or diagnoses any condition, and nothing here is a dosing instruction.
| Weight | 0.0132277 lbs |
|---|---|
| Dimensions | 1 × 1 × 2 in |
Every batch we publish a third-party certificate of analysis. Get told when a new one lands, and when a sold-out peptide is back.
